Innoblative Secures the US FDA’s IDE Approval of SIRA Electrosurgical Device for Breast Cancer Patients
Shots:
- The US FDA has granted IDE approval to initiate US feasibility study of SIRA radiofrequency ablation (RFA) electrosurgical device for pts undergoing breast-conservation surgery (BCS)
- SIRA device is a single-use applicator designed to deliver circumferential RFA to the post-lumpectomy cavity during breast-conserving surgery to provide consistent ablation depth & increased confidence in margin treatment compared to conventional RF systems
- SIRA device is designed to reduce positive margin rates, minimize BCS reoperations, & provide one-time, non-ionizing alternative to radiation therapy for eligible pts
Ref: Innoblative | Image: Innoblative
Related News:- Elixir Medical Reports European MDR CE Mark Approval & Launch of LithiX Hertz Contact IVL System
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
